HomeMVIR • STO
Medivir AB
kr 2.97
Sep 10, 4:13:22 PM GMT+2 · SEK · STO · Disclaimer
StockSE listed security
Previous close
kr 3.00
Day range
kr 2.87 - kr 3.00
Year range
kr 2.33 - kr 6.76
Market cap
333.14M SEK
Avg Volume
95.86K
P/E ratio
-
Dividend yield
-
Primary exchange
STO
Market news
Financials
Income Statement
Revenue
Net income
(SEK)Jun 2024Y/Y change
Revenue
1.10M-45.00%
Operating expense
8.30M0.00%
Net income
-36.00M-35.34%
Net profit margin
-3.27K-146.07%
Earnings per share
-0.3231.91%
EBITDA
-36.80M-37.31%
Effective tax rate
Total assets
Total liabilities
(SEK)Jun 2024Y/Y change
Cash and short-term investments
126.60M52.90%
Total assets
239.20M19.72%
Total liabilities
63.20M21.77%
Total equity
176.00M
Shares outstanding
112.17M
Price to book
1.91
Return on assets
-37.08%
Return on capital
-45.92%
Net change in cash
(SEK)Jun 2024Y/Y change
Net income
-36.00M-35.34%
Cash from operations
-26.30M-46.93%
Cash from investing
Cash from financing
-400.00K-300.00%
Net change in cash
-26.80M-48.89%
Free cash flow
-14.04M-57.95%
About
Medivir is a Swedish biotech company. Medivir focuses its research focus on oncology and particularly on innovative pharmaceuticals that meet substantial unmet medical needs. The pharmaceutical development work is conducted both in-house and through partnerships, usually with global pharmaceutical companies. Medivir has a leading expertise in the design of protease inhibitors and in the science of nucleotides and nucleosides. Medivir is listed on the Nasdaq Stockholm Mid Cap List. In February 2020, Medivir announced that the company has signed a licensing agreement for Xerclear with Chinese company Shijiazhuang Yuanmai Biotechnology Co Ltd. The agreement gives SYB the right to register, manufacture and market the product in China. Wikipedia
Founded
1988
Employees
10
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu